Fall 2026
Technology Co-op
Posted on 5/18/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
$25.50 - $33/hr
No H1B Sponsorship
New Hope, PA, USA + 9 more
More locations: West Chester, PA, USA | Bridgewater Township, NJ, USA | Horsham, PA, USA | Shepherdsville, KY, USA | Irvine, CA, USA | Santa Clara, CA, USA | Edison, NJ, USA | Ambler, PA, USA | Peabody, MA, USA
Hybrid
 Software Engineering (1) |
|---|
- Permanent US work authorization without the need for sponsorship now, or in the future (F1 or H1B requires sponsorship in future)
- Have a cumulative GPA of 3.0 or higher, which is reflective of all college coursework
- Be currently enrolled and pursuing a Bachelor’s or Master’s degree
- Preferred fields include Information Management, Information Technology, Computer Engineering, Management Information Systems, Computer Science, Software Engineering / Development, Data Science, Cybersecurity, Graphic Design or Mathematics
- Able and committed to working full time (40 hours a week) from June 22, 2026, through December 18, 2026
- By start date, must be considered an undergraduate sophomore or above
- Work within specialized groups in the Johnson & Johnson Technology organization to build solutions for business partners and drive value.
- Contribute individually and/or as a team member to support a designated technology area.
- Work with key stakeholders to accomplish goals and objectives to support the Johnson & Johnson Technology project/program portfolio.
- Build awareness and experience of key capability skills in support of the Johnson & Johnson Technology Strategy.
- Conduct data and process analysis to support development of key solutions.
- Information Management
- Information Technology
- Computer Engineering
- Management Information Systems
- Computer Science
- Software Engineering / Development
- Data Science
- Cybersecurity
- Graphic Design
- Mathematics
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Your Connections
People at Johnson & Johnson who can refer or advise you
Simplify's Take
What believers are saying
- Firefly Bio expands J&J's KRAS-focused oncology platform for hard-to-treat tumors.
- TREMFYA, CARVYKTI, and RYBREVANT are offsetting STELARA's biosimilar decline.
- Jacksonville and Pennsylvania investments deepen manufacturing capacity and support future growth.
What critics are saying
- STELARA's biosimilar erosion continues to pressure immunology revenue until replacements scale.
- Talc litigation remains a recurring cash, reserve, and reputational overhang.
- Firefly Bio's clinical-stage assets face efficacy risk before meaningful oncology contribution.
What makes Johnson & Johnson unique
- J&J combines pharmaceuticals, MedTech, and consumer health across global markets.
- Its 2026 pipeline spans oncology, immunology, neuroscience, and cardiovascular programs.
- AAA credit and 64 straight dividend increases signal exceptional financial durability.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -11%1 year growth
↓ -11%2 year growth
↓ -10%• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation
Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.
Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.
Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.
Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.